Seeking Alpha
09 Jun 2026, 23:32 UTC · 10h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Ultragenyx expects to release key Phase III Angelman syndrome data in the second half of the year. — Phase III results for a 'biggest upside product' are primary catalysts for biotech valuation shifts.
+0.80The company is targeting a potential path to profitability by 2027. — Providing a clear timeline for profitability reduces long-term risk for investors in growth-stage pharma.
+0.50Long-term Phase II data for the Angelman program shows durable effects over 3-4 years with no cumulative safety concerns. — Positive long-term safety and efficacy data increase the probability of success for the upcoming Phase III trial.
+0.40Continue reading
6 related stories
Top 2 movers · tap to explore
The company previously missed an OI (objective endpoint/outcome) in a Phase III trial earlier in the year. — Past clinical misses introduce a risk premium and historical precedent for failure in the pipeline.
Which stocks this story touches
The company has a high-upside product in Angelman syndrome with positive long-term Phase II data and a potential path to profitability in 2027, despite a previous Phase III setback.
Goldman Sachs is mentioned only as the host of the healthcare conference.
Go deeper
You just saw which tickers this one story hits. A free account turns that into a standing screen: the movers delivered on schedule, before the chart catches up.
On this page · free
In the platform
Free account, 30 seconds. No credit card. Covers all 10 tickers this story moves.
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Screener bridge
GS showed up in this week’s NIS Momentum screen.
Get the full NIS Momentum results every Friday at 4PM ET — free via email or Telegram.
Seeking Alpha
1h ago
